Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported a third-quarter net loss of $20.3 million while advancing soquelitinib trials across cancer and immune diseases. The loss compared with $10.2 million a year earlier. Cash, cash equivalents and marketable securities totaled $202.9 million at September 30, 2026, versus $56.8 million at December 31, 2025; Corvus expects funding into the second quarter of 2028.
Enrollment continues in the Phase 3 peripheral T-cell lymphoma and Phase 2 atopic dermatitis trials. Partner Angel Pharmaceuticals completed its first atopic dermatitis cohort, with results anticipated in March 2027. Initial hidradenitis suppurativa data are anticipated in the first half of 2027; Corvus plans an asthma trial by Q1 2027. Three patients with autoimmune lymphoproliferative syndrome responded after 360 days of treatment, with no grade 3 or 4 adverse events. Quarterly research spending rose to $17.8 million from $8.5 million.
Corvus Pharmaceuticals (CRVS) will present initial Phase 2 soquelitinib data in autoimmune lymphoproliferative syndrome at the American Society of Hematology meeting. The poster presentation is scheduled for December 14, 2026, in New Orleans. The ongoing trial was initiated by the National Institute of Allergy and Infectious Diseases.
As of August 3, 2026, three patients had completed one year of treatment at 200 mg twice daily. Treatment was well tolerated, with no grade 3 or 4 adverse events and no therapy interruptions. All three discontinued background medications, including steroids, and reported improvement in symptoms related to ALPS, a rare genetic disease with no cure or approved treatment. Corvus believes the findings support continued enrollment and plans to explore longer treatment durations and enroll younger pediatric patients.
Corvus Pharmaceuticals (Nasdaq: CRVS) will provide a business update and report third quarter 2026 financial results on November 5, 2026. The company will host a conference call and webcast at 4:30 pm ET (1:30 pm PT). The live webcast will be accessible through the investor relations section of Corvus’ website, with a replay available on the website for 90 days.
Corvus Pharmaceuticals (CRVS) has begun enrollment in a Phase 1b trial of soquelitinib for patients with moderate to severe hidradenitis suppurativa.
The trial is designed to enroll up to 25 patients aged 18 and older. All patients will receive 200 mg twice daily for 12 weeks, followed by 90 days without treatment. The primary endpoint is safety and tolerability. The key efficacy endpoint measures the proportion achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 50/75 at week 12; skin and blood biomarkers will also be evaluated. Corvus aims to establish proof of concept and examine effects on Th17 immune-cell biology.
This is soquelitinib’s fourth indication in clinical development, alongside a registrational Phase 3 trial for peripheral T cell lymphoma and Phase 2 trials for atopic dermatitis and autoimmune lymphoproliferative syndrome. Corvus plans to start a Phase 2 asthma trial later this year.
Corvus Pharmaceuticals (CRVS) will participate in the 2026 Cantor Global Healthcare Conference in New York, NY, with leadership hosting one-on-one investor meetings and a fireside chat on September 10, 2026.
The fireside chat is scheduled for 1:00 pm ET (10:00 am PT). A live webcast, available via the company’s investor relations website, will remain accessible for 90 days after the event.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported peer‑reviewed final data in Blood from its Phase 1/1b trial of soquelitinib in T cell lymphoma, supporting its development in oncology and immune/inflammatory diseases, according to Corvus.
The study enrolled 75 heavily pre‑treated patients across multiple T cell lymphoma subtypes. Doses up to 600 mg twice daily were well tolerated with no dose‑limiting toxicities, significant adverse events, myelosuppression or immunosuppression. A 200 mg twice‑daily dose was chosen for expansion based on complete ITK target occupancy.
In the 200 mg cohort (N=36), patients with one to three prior therapies (N=24) achieved 9 objective responses (six complete, three partial), median progression‑free survival of 6.2 months, 30% progression‑free at 18 months, and median overall survival of 28.1 months with 67% alive at 24 months. Corvus highlighted a mechanism involving selective ITK inhibition, Th1 skewing and both tumor‑intrinsic and microenvironment effects.
Corvus is enrolling a registration Phase 3 trial in relapsed/refractory PTCL (150 patients) comparing soquelitinib to physician’s choice of belinostat or pralatrexate, with progression‑free survival as the primary endpoint. Soquelitinib has FDA Orphan Drug and Fast Track designations for T cell lymphoma and relapsed/refractory PTCL, respectively.
Corvus Pharmaceuticals (Nasdaq: CRVS) reported a Q2 2026 net loss of $18.0 million versus $8.0 million a year earlier, driven mainly by higher soquelitinib clinical trial and personnel costs. Research and development expenses rose to $16.0 million from $7.9 million. Cash, cash equivalents and marketable securities were $215.2 million at June 30, 2026, including $189.4 million of net financing proceeds received in January, which Corvus expects will fund operations into the second quarter of 2028.
Corvus highlighted ongoing enrollment in its registrational Phase 3 relapsed/refractory PTCL trial and Phase 2 atopic dermatitis trial for soquelitinib, positive Phase 1 atopic dermatitis data presented at SID, continued ALPS collaboration with NIAID, and expanded collaboration with Angel Pharmaceuticals, including a $5.0 million equity investment.
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report its second quarter 2026 financial results.
According to Corvus Pharmaceuticals, domestic investors can join by dialing 1-800-717-1738, while international participants can use 1-646-307-1865 or an instant telephone access link. The live webcast will be available through the investor relations section of the company’s website, with a replay accessible for 90 days.
Corvus Pharmaceuticals (Nasdaq: CRVS) is investing $5 million in a new $13.5 million financing for Angel Pharmaceuticals, its China partner and largest equity holding. The funds are expected to support soquelitinib development in China for atopic dermatitis and asthma.
The financing backs Angel’s ongoing Phase 1b/2 atopic dermatitis trial and a planned Phase 2 asthma trial, with initial atopic dermatitis Phase 1b data anticipated in late 2026 and asthma trial initiation expected in early 2027.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
The Jefferies presentation is on June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is on June 8, 2026 at 11:20 AM ET. Live webcasts and 90-day replays will be available via Corvus' investor relations website.